Who is sponsoring NCT00944372?

NCT00944372 is sponsored by Mallinckrodt.

What condition does NCT00944372 study?

NCT00944372 studies Solid Tumors.

What drugs are being tested in NCT00944372?

Interventions: Indium In-111 pentetreotide.

What is the status of NCT00944372?

NCT00944372 is currently TERMINATED.

Last reviewed 2016-09-08 · How we verify

An Open-Label, Multi-Center, Phase 4 Study to Evaluate the Effect of Age (Geriatric) and Renal Function on the Safety, Efficacy (Sensitivity, Specificity) and Pharmacokinetics of OctreoScan in Patients Referred for Scintigraphy of All Solid Tumors With a High Suspicion of Containing Somatostatin Receptor Positive Tissue

NCT00944372 Phase 4 TERMINATED

The objective of this study was to evaluate the effect of age (geriatric) and renal function on the safety, efficacy and pharmacokinetics of OctreoScan at the recommended clinical dose in this patient population.

Details

Lead sponsor	Mallinckrodt
Phase	Phase 4
Status	TERMINATED
Enrolment	150
Start date	2003-07
Completion	2005-08

Conditions

Solid Tumors

Interventions

Indium In-111 pentetreotide

Primary outcomes

Assessment of OctreoScan diagnostic sensitivity for detecting tumor(s) confirmed as somatostatin receptor positive by biopsy with immunohistochemistry analysis — Through 24 hours post dose

Countries

United States